Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report

Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report

Abstract Background Dasatinib is a second-generation tyrosine kinase inhibitor that is indicated for the treatment of patients with chronic myeloid leukemia. Here, we report the case of a man with nephrotic syndrome that was caused by dasatinib. Case presentation A 40-year-old man with chronic myelo...

Full description

Bibliographic Details
Main Authors: Shoko Ochiai, Yuji Sato, Akihiro Minakawa, Akihiro Fukuda, Shouichi Fujimoto
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Nephrology
Subjects:
Drug-related nephrotic syndrome
Tyrosine kinase inhibitor
Dasatinib
Fibrillary glomerulonephritis
Nephrotic syndrome
Vascular endothelial growth factor
Online Access:http://link.springer.com/article/10.1186/s12882-019-1273-6

Internet

http://link.springer.com/article/10.1186/s12882-019-1273-6

Similar Items